APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Measles Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Live Attenuated Measles Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174008370330 December 2025190 pages

Choose your research edition.

Industry ResearchLive Attenuated Measles Vaccine Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Measles Vaccine Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Live Attenuated Measles Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Measles Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Measles Vaccine Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Live Attenuated Measles Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Live Attenuated Measles Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Live Attenuated Measles Vaccine include GSK, Bavarian Nordic, CSL Limited, Emergent Biosolutions, Medimmune, Sanofi-Pasteur, Serum Institute of India, Beijing Institute of Biological Products Co., Ltd and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live Attenuated Measles Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Attenuated Measles Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Attenuated Measles Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Measles Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Attenuated Measles Vaccine Segment by Company

GSK

Bavarian Nordic

CSL Limited

Emergent Biosolutions

Medimmune

Sanofi-Pasteur

Serum Institute of India

Beijing Institute of Biological Products Co., Ltd

Pfizer

Lanzhou Institute of Biological Products Co., Ltd

Merck

Novartis

Johnson & Johnson

Shanghai Institute of Biological Products Co., Ltd

Wuhan Institute of Biological Products Co., Ltd

Changchun Qijian Biological Products Co., Ltd

Live Attenuated Measles Vaccine Segment by Type

Liquid

Powder

Live Attenuated Measles Vaccine Segment by Application

Hospital

Clinic

Live Attenuated Measles Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Measles Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Measles Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Measles Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Measles Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Live Attenuated Measles Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Live Attenuated Measles Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Live Attenuated Measles Vaccine Industry Trends Table 2. Live Attenuated Measles Vaccine Industry Drivers Table 3. Live Attenuated Measles Vaccine Industry Opportunities and Challenges Table 4. Live Attenuated Measles Vaccine Industry Restraints Table 5. Global Live Attenuated Measles Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Live Attenuated Measles Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers Table 9. Global Live Attenuated Measles Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Live Attenuated Measles Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Live Attenuated Measles Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Live Attenuated Measles Vaccine Manufacturers, Product Type & Application Table 13. Global Live Attenuated Measles Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Live Attenuated Measles Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Liquid Table 17. Major Manufacturers of Powder Table 18. Global Live Attenuated Measles Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Live Attenuated Measles Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global Live Attenuated Measles Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Live Attenuated Measles Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Live Attenuated Measles Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global Live Attenuated Measles Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Global Live Attenuated Measles Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Live Attenuated Measles Vaccine Sales by Application (2021-2026) & (K Units) Table 32. Global Live Attenuated Measles Vaccine Sales by Application (2027-2032) & (K Units) Table 33. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2026) Table 34. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2027-2032) Table 35. Global Live Attenuated Measles Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Live Attenuated Measles Vaccine Revenue by Application (2021-2026) & (K Units) Table 37. Global Live Attenuated Measles Vaccine Revenue by Application (2027-2032) & (K Units) Table 38. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2026) Table 39. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2027-2032) Table 40. Global Live Attenuated Measles Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Live Attenuated Measles Vaccine Sales by Region (2021-2026) & (K Units) Table 42. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2021-2026) Table 43. Global Live Attenuated Measles Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Live Attenuated Measles Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Live Attenuated Measles Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 47. North America Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 48. Europe Live Attenuated Measles Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 50. Europe Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Live Attenuated Measles Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Live Attenuated Measles Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2027-2032) & (K Units) Table 57. Global Live Attenuated Measles Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Live Attenuated Measles Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Live Attenuated Measles Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2021-2026) Table 61. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2027-2032) Table 62. GSK Company Information Table 63. GSK Business Overview Table 64. GSK Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. GSK Live Attenuated Measles Vaccine Product Portfolio Table 66. GSK Recent Development Table 67. Bavarian Nordic Company Information Table 68. Bavarian Nordic Business Overview Table 69. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio Table 71. Bavarian Nordic Recent Development Table 72. CSL Limited Company Information Table 73. CSL Limited Business Overview Table 74. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. CSL Limited Live Attenuated Measles Vaccine Product Portfolio Table 76. CSL Limited Recent Development Table 77. Emergent Biosolutions Company Information Table 78. Emergent Biosolutions Business Overview Table 79. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio Table 81. Emergent Biosolutions Recent Development Table 82. Medimmune Company Information Table 83. Medimmune Business Overview Table 84. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Medimmune Live Attenuated Measles Vaccine Product Portfolio Table 86. Medimmune Recent Development Table 87. Sanofi-Pasteur Company Information Table 88. Sanofi-Pasteur Business Overview Table 89. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio Table 91. Sanofi-Pasteur Recent Development Table 92. Serum Institute of India Company Information Table 93. Serum Institute of India Business Overview Table 94. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio Table 96. Serum Institute of India Recent Development Table 97. Beijing Institute of Biological Products Co., Ltd Company Information Table 98. Beijing Institute of Biological Products Co., Ltd Business Overview Table 99. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 101. Beijing Institute of Biological Products Co., Ltd Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Pfizer Live Attenuated Measles Vaccine Product Portfolio Table 106. Pfizer Recent Development Table 107. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 108. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 109. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 111. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 112. Merck Company Information Table 113. Merck Business Overview Table 114. Merck Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Merck Live Attenuated Measles Vaccine Product Portfolio Table 116. Merck Recent Development Table 117. Novartis Company Information Table 118. Novartis Business Overview Table 119. Novartis Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Novartis Live Attenuated Measles Vaccine Product Portfolio Table 121. Novartis Recent Development Table 122. Johnson & Johnson Company Information Table 123. Johnson & Johnson Business Overview Table 124. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio Table 126. Johnson & Johnson Recent Development Table 127. Shanghai Institute of Biological Products Co., Ltd Company Information Table 128. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 129. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 131. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 132. Wuhan Institute of Biological Products Co., Ltd Company Information Table 133. Wuhan Institute of Biological Products Co., Ltd Business Overview Table 134. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 136. Wuhan Institute of Biological Products Co., Ltd Recent Development Table 137. Changchun Qijian Biological Products Co., Ltd Company Information Table 138. Changchun Qijian Biological Products Co., Ltd Business Overview Table 139. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio Table 141. Changchun Qijian Biological Products Co., Ltd Recent Development Table 142. Key Raw Materials Table 143. Raw Materials Key Suppliers Table 144. Live Attenuated Measles Vaccine Distributors List Table 145. Live Attenuated Measles Vaccine Customers List Table 146. Research Programs/Design for This Report Table 147. Authors List of This Report Table 148. Secondary Sources Table 149. Primary Sources List of Figures Figure 1. Live Attenuated Measles Vaccine Product Image Figure 2. Global Live Attenuated Measles Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Measles Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Measles Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Live Attenuated Measles Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Live Attenuated Measles Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Liquid Image Figure 9. Powder Image Figure 10. Global Live Attenuated Measles Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Live Attenuated Measles Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Live Attenuated Measles Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Live Attenuated Measles Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Global Live Attenuated Measles Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Live Attenuated Measles Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2032) Figure 21. Global Live Attenuated Measles Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Live Attenuated Measles Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 26. U.S. Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 31. Germany Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 38. China Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share by Country (2021-2032) Figure 46. Brazil Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Live Attenuated Measles Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Live Attenuated Measles Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Live Attenuated Measles Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Figure 57. North America Live Attenuated Measles Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Live Attenuated Measles Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Live Attenuated Measles Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Live Attenuated Measles Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Live Attenuated Measles Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Live Attenuated Measles Vaccine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Live Attenuated Measles Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Liquid
  • Powder
Applications
  • Hospital
  • Clinic
Companies covered
  • GSK
  • Bavarian Nordic
  • CSL Limited
  • Emergent Biosolutions
  • Medimmune
  • Sanofi-Pasteur
  • Serum Institute of India
  • Beijing Institute of Biological Products Co., Ltd
  • Pfizer
  • Lanzhou Institute of Biological Products Co., Ltd
  • Merck
  • Novartis
  • Johnson & Johnson
  • Shanghai Institute of Biological Products Co., Ltd
  • Wuhan Institute of Biological Products Co., Ltd
  • Changchun Qijian Biological Products Co., Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Live Attenuated Measles Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Live Attenuated Measles Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Live Attenuated Measles Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Live Attenuated Measles Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Live Attenuated Measles Vaccine Market Dynamics
  1. 2.1 Live Attenuated Measles Vaccine Industry Trends
  2. 2.2 Live Attenuated Measles Vaccine Industry Drivers
  3. 2.3 Live Attenuated Measles Vaccine Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Measles Vaccine Industry Restraints
3 Live Attenuated Measles Vaccine Market by Manufacturers
  1. 3.1 Global Live Attenuated Measles Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Live Attenuated Measles Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Live Attenuated Measles Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Live Attenuated Measles Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Live Attenuated Measles Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Live Attenuated Measles Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Live Attenuated Measles Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Live Attenuated Measles Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Live Attenuated Measles Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Live Attenuated Measles Vaccine Tier 1, Tier 2, and Tier 3
4 Live Attenuated Measles Vaccine Market by Type
  1. 4.1 Live Attenuated Measles Vaccine Type Introduction
  2. 4.1.1 Liquid
  3. 4.1.2 Powder
  4. 4.2 Global Live Attenuated Measles Vaccine Sales by Type
  5. 4.2.1 Global Live Attenuated Measles Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live Attenuated Measles Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Live Attenuated Measles Vaccine Revenue by Type
  9. 4.3.1 Global Live Attenuated Measles Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Live Attenuated Measles Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2021-2032)
5 Live Attenuated Measles Vaccine Market by Application
  1. 5.1 Live Attenuated Measles Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Live Attenuated Measles Vaccine Sales by Application
  5. 5.2.1 Global Live Attenuated Measles Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Live Attenuated Measles Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Live Attenuated Measles Vaccine Revenue by Application
  9. 5.3.1 Global Live Attenuated Measles Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Live Attenuated Measles Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2021-2032)
6 Global Live Attenuated Measles Vaccine Sales by Region
  1. 6.1 Global Live Attenuated Measles Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Attenuated Measles Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Live Attenuated Measles Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Live Attenuated Measles Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Live Attenuated Measles Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Live Attenuated Measles Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Live Attenuated Measles Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Live Attenuated Measles Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Live Attenuated Measles Vaccine Revenue by Region
  1. 7.1 Global Live Attenuated Measles Vaccine Revenue by Region
  2. 7.1.1 Global Live Attenuated Measles Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Live Attenuated Measles Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Live Attenuated Measles Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Live Attenuated Measles Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Live Attenuated Measles Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Live Attenuated Measles Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Live Attenuated Measles Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Live Attenuated Measles Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Live Attenuated Measles Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Live Attenuated Measles Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Live Attenuated Measles Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Bavarian Nordic
  8. 8.2.1 Bavarian Nordic Company Information
  9. 8.2.2 Bavarian Nordic Business Overview
  10. 8.2.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
  12. 8.2.5 Bavarian Nordic Recent Developments
  13. 8.3 CSL Limited
  14. 8.3.1 CSL Limited Company Information
  15. 8.3.2 CSL Limited Business Overview
  16. 8.3.3 CSL Limited Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
  18. 8.3.5 CSL Limited Recent Developments
  19. 8.4 Emergent Biosolutions
  20. 8.4.1 Emergent Biosolutions Company Information
  21. 8.4.2 Emergent Biosolutions Business Overview
  22. 8.4.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
  24. 8.4.5 Emergent Biosolutions Recent Developments
  25. 8.5 Medimmune
  26. 8.5.1 Medimmune Company Information
  27. 8.5.2 Medimmune Business Overview
  28. 8.5.3 Medimmune Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
  30. 8.5.5 Medimmune Recent Developments
  31. 8.6 Sanofi-Pasteur
  32. 8.6.1 Sanofi-Pasteur Company Information
  33. 8.6.2 Sanofi-Pasteur Business Overview
  34. 8.6.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
  36. 8.6.5 Sanofi-Pasteur Recent Developments
  37. 8.7 Serum Institute of India
  38. 8.7.1 Serum Institute of India Company Information
  39. 8.7.2 Serum Institute of India Business Overview
  40. 8.7.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
  42. 8.7.5 Serum Institute of India Recent Developments
  43. 8.8 Beijing Institute of Biological Products Co., Ltd
  44. 8.8.1 Beijing Institute of Biological Products Co., Ltd Company Information
  45. 8.8.2 Beijing Institute of Biological Products Co., Ltd Business Overview
  46. 8.8.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  48. 8.8.5 Beijing Institute of Biological Products Co., Ltd Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Lanzhou Institute of Biological Products Co., Ltd
  56. 8.10.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  57. 8.10.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  58. 8.10.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  60. 8.10.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  61. 8.11 Merck
  62. 8.11.1 Merck Company Information
  63. 8.11.2 Merck Business Overview
  64. 8.11.3 Merck Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Merck Live Attenuated Measles Vaccine Product Portfolio
  66. 8.11.5 Merck Recent Developments
  67. 8.12 Novartis
  68. 8.12.1 Novartis Company Information
  69. 8.12.2 Novartis Business Overview
  70. 8.12.3 Novartis Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
  72. 8.12.5 Novartis Recent Developments
  73. 8.13 Johnson & Johnson
  74. 8.13.1 Johnson & Johnson Company Information
  75. 8.13.2 Johnson & Johnson Business Overview
  76. 8.13.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
  78. 8.13.5 Johnson & Johnson Recent Developments
  79. 8.14 Shanghai Institute of Biological Products Co., Ltd
  80. 8.14.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  81. 8.14.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  82. 8.14.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  84. 8.14.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  85. 8.15 Wuhan Institute of Biological Products Co., Ltd
  86. 8.15.1 Wuhan Institute of Biological Products Co., Ltd Company Information
  87. 8.15.2 Wuhan Institute of Biological Products Co., Ltd Business Overview
  88. 8.15.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  90. 8.15.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments
  91. 8.16 Changchun Qijian Biological Products Co., Ltd
  92. 8.16.1 Changchun Qijian Biological Products Co., Ltd Company Information
  93. 8.16.2 Changchun Qijian Biological Products Co., Ltd Business Overview
  94. 8.16.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
  96. 8.16.5 Changchun Qijian Biological Products Co., Ltd Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live Attenuated Measles Vaccine Value Chain Analysis
  2. 9.1.1 Live Attenuated Measles Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live Attenuated Measles Vaccine Production Mode & Process
  6. 9.2 Live Attenuated Measles Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live Attenuated Measles Vaccine Distributors
  9. 9.2.3 Live Attenuated Measles Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst